{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "SARS-CoV-2", "coronavirus 3CLpro", "molecular docking", "natural product"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "32367767", "DateCompleted": {"Year": "2021", "Month": "06", "Day": "18"}, "DateRevised": {"Year": "2021", "Month": "06", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "05", "Day": "18"}], "Language": ["eng"], "ELocationID": ["10.1080/07391102.2020.1764868"], "Journal": {"ISSN": "1538-0254", "JournalIssue": {"Volume": "39", "Issue": "9", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "Journal of biomolecular structure & dynamics", "ISOAbbreviation": "J Biomol Struct Dyn"}, "ArticleTitle": "Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL<sup>pro</sup>): an <i>in silico</i> screening of alkaloids and terpenoids from African medicinal plants.", "Pagination": {"StartPage": "3396", "EndPage": "3408", "MedlinePgn": "3396-3408"}, "Abstract": {"AbstractText": ["The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL<sup>pro</sup>), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL<sup>pro</sup> using <i>in silico</i> approach. Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL<sup>pro</sup> of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL<sup>pro</sup> were further docked to the 3CL<sup>pro</sup> of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL<sup>pro</sup>-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis. This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL<sup>pro</sup>, and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-<i>Epi</i>bryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL<sup>pro</sup> were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic.Communicated by Ramaswamy H. Sarma."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, Salem University, Lokoja, Nigeria."}], "LastName": "Gyebi", "ForeName": "Gideon A", "Initials": "GA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, KolaDaisi University, Ibadan, Nigeria."}], "LastName": "Ogunro", "ForeName": "Olalekan B", "Initials": "OB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Life Sciences, University of Ilorin, Ilorin, Nigeria."}], "LastName": "Adegunloye", "ForeName": "Adegbenro P", "Initials": "AP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, Salem University, Lokoja, Nigeria."}], "LastName": "Ogunyemi", "ForeName": "Oludare M", "Initials": "OM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Nigeria."}], "LastName": "Afolabi", "ForeName": "Saheed O", "Initials": "SO"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Biomol Struct Dyn", "NlmUniqueID": "8404176", "ISSNLinking": "0739-1102"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Terpenes"}, {"RegistryNumber": "EC 3.4.21.39", "NameOfSubstance": "Chymases"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Alkaloids"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Chymases"}, {"QualifierName": [], "DescriptorName": "Computer Simulation"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Protease Inhibitors"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Terpenes"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Aanouz I., Belhassan A., El Khatabi K., Lakhlifi T., El Idrissi M., & Bouachrine M. (2020). Moroccan Medicinal plants as inhibitors of COVID-19: Computational investigations. Journal of Biomolecular Structure and Dynamics (just-accepted), 1\u201312.", "ArticleIdList": ["PMC7212546", "32306860"]}, {"Citation": "Amoa Ongu\u00e9n\u00e9 P., Ntie-Kang F., Lifongo L. L., Ndom J. C., Sippl W., & Mbaze L. M. (2013). The potential of anti-malarial compounds derived from African medicinal plants, part I: A pharmacological evaluation of alkaloids and terpenoids. Malaria Journal, 12, 449 10.1186/1475-2875-12-449", "ArticleIdList": ["10.1186/1475-2875-12-449", "PMC3878730", "24330395"]}, {"Citation": "Anand K., Ziebuhr J., Wadhwani P., Mesters J. R., & Hilgenfeld R. (2003). Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science (New York, N.Y.).), 300(5626), 1763\u20131767. 10.1126/science.1085658", "ArticleIdList": ["10.1126/science.1085658", "12746549"]}, {"Citation": "Berry M., Fielding B. C., & Gamieldien J. (2015). Potential broad spectrum inhibitors of the coronavirus 3CLpro: A virtual screening and structure-based drug design study. Viruses , 7(12), 6642\u20136660. 10.3390/v7122963", "ArticleIdList": ["10.3390/v7122963", "PMC4690886", "26694449"]}, {"Citation": "Boopathi S., Poma A. B., & Kolandaivel P. (2020). Novel 2019 Coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. Journal of Biomolecular Structure and Dynamics (just-accepted), 1\u201314.", "ArticleIdList": ["PMC7196923", "32306836"]}, {"Citation": "Cascella M., Rajnik M., Cuomo A., Dulebohn S. C., & Di Napoli R. (2020). Features, evaluation and treatment coronavirus (COVID-19). StatPearls [Internet]. StatPearls Publishing.", "ArticleIdList": ["32150360"]}, {"Citation": "Chan J. F. W., Chan K.-H., Kao R. Y. T., To K. K. W., Zheng B.-J., Li C. P. Y., Li P. T. W., Dai J., Mok F. K. Y., Chen H., Hayden F. G., & Yuen K.-Y. (2013). Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. The Journal of Infection, 67(6), 606\u2013616. 10.1016/j.jinf.2013.09.029", "ArticleIdList": ["10.1016/j.jinf.2013.09.029", "PMC7112612", "24096239"]}, {"Citation": "Chen Y. W., Yiu C.-P B., & Wong K.-Y. (2020). Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research, 9, 129 10.12688/f1000research.22457.1", "ArticleIdList": ["10.12688/f1000research.22457.1", "PMC7062204", "32194944"]}, {"Citation": "Cheng F., Li W., Zhou Y., Shen J., Wu Z., Liu G., Lee P. W., & Tang Y. (2012). admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. Journal of Chemical Information and Modeling, 52(11), 3099\u20133105. 10.1021/ci300367a", "ArticleIdList": ["10.1021/ci300367a", "23092397"]}, {"Citation": "de Wilde A. H., Jochmans D., Posthuma C. C., Zevenhoven-Dobbe J. C., van Nieuwkoop S., Bestebroer T. M., van den Hoogen B. G., Neyts J., & Snijder E. J. (2014). Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy, 58(8), 4875\u20134884. 10.1128/aac.03011-14", "ArticleIdList": ["10.1128/aac.03011-14", "PMC4136071", "24841269"]}, {"Citation": "Dong E., Du H., & Gardner L. (2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infectious Diseases. 10.1016/s1473-3099(20)30120-1", "ArticleIdList": ["10.1016/s1473-3099(20)30120-1", "PMC7159018", "32087114"]}, {"Citation": "Dyall J., Coleman C. M., Hart B. J., Venkataraman T., Holbrook M. R., Kindrachuk J., Johnson R. F., Olinger G. G., Jahrling P. B., Laidlaw M., Johansen L. M., Lear-Rooney C. M., Glass P. J., Hensley L. E., & Frieman M. B. (2014). Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy, 58(8), 4885\u20134893. 10.1128/aac.03036-14", "ArticleIdList": ["10.1128/aac.03036-14", "PMC4136000", "24841273"]}, {"Citation": "Elfiky A. A., & Azzam E. B. (2020). Novel Guanosine Derivatives against MERS CoV polymerase: An in silico perspective. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201312.", "ArticleIdList": ["PMC7189410", "32306854"]}, {"Citation": "Elmezayen A. D., Al-Obaidi A., \u015eahin A. T., & Yelek\u00e7i K. (2020). Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201312.", "ArticleIdList": ["PMC7189413", "32306862"]}, {"Citation": "Gupta M. K., Vemula S., Donde R., Gouda G., Behera L., & Vadde R. (2020). In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Biomolecular Structure and Dynamics, 1\u201311. 10.1080/07391102.2020.1751300", "ArticleIdList": ["10.1080/07391102.2020.1751300", "PMC7171389", "32238078"]}, {"Citation": "Hasan A., Paray B. A., Hussain A., Qadir F. A., Attar F., Aziz F. M., & Mehrabi M. (2020). A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201313.", "ArticleIdList": ["PMC7189411", "32274964"]}, {"Citation": "Jo S., Kim S., Shin D. H., & Kim M.-S. (2020). Inhibition of SARS-CoV 3CL protease by flavonoids. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 145\u2013151. 10.1080/14756366.2019.1690480", "ArticleIdList": ["10.1080/14756366.2019.1690480", "PMC6882434", "31724441"]}, {"Citation": "Khan R. J., Jha R. K., Amera G., Jain M., Singh E., Pathak A., & Singh A. K. (2020). Targeting SARS-CoV-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2019-O-ribosemethyltransferase. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201340.", "ArticleIdList": ["PMC7189412", "32266873"]}, {"Citation": "Khan S. A., Zia K., Ashraf S., Uddin R., & Ul-Haq Z. (2020). Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. Journal of Biomolecular Structure and Dynamics, 1\u201310. 10.1080/07391102.2020.1751298", "ArticleIdList": ["10.1080/07391102.2020.1751298", "32238094"]}, {"Citation": "Lessene G., Czabotar P. E., Sleebs B. E., Zobel K., Lowes K. N., Adams J. M., Baell J. B., Colman P. M., Deshayes K., Fairbrother W. J., Flygare J. A., Gibbons P., Kersten W. J. A., Kulasegaram S., Moss R. M., Parisot J. P., Smith B. J., Street I. P., Yang H., Huang D. C. S., & Watson K. G. (2013). Structure-guided design of a selective BCL-X(L) inhibitor. Nature Chemical Biology, 9(6), 390\u2013397. 10.1038/nchembio.1246", "ArticleIdList": ["10.1038/nchembio.1246", "23603658"]}, {"Citation": "Li J. Y., You Z., Wang Q., Zhou Z. J., Qiu Y., Luo R., & Ge X. Y. (2020). The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes and Infection, 22(2), 80\u201385. 10.1016/j.micinf.2020.02.002", "ArticleIdList": ["10.1016/j.micinf.2020.02.002", "PMC7079563", "32087334"]}, {"Citation": "Lipinski C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235\u2013249. 10.1016/S1056-8719(00)00107-6", "ArticleIdList": ["10.1016/S1056-8719(00)00107-6", "11274893"]}, {"Citation": "Muralidharan N., Sakthivel R., Velmurugan D., & Gromiha M. M. (2020). Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u20137.", "ArticleIdList": ["32248766"]}, {"Citation": "Ndhlala A. R., Amoo S. O., Ncube B., Moyo M., Nair J. J., & Van Staden J. (2013). Antibacterial, antifungal, and antiviral activities of African medicinal plants In Medicinal plant research in Africa (pp. 621\u2013659): Elsevier."}, {"Citation": "Nickel J., Gohlke B.-O., Erehman J., Banerjee P., Rong W. W., Goede A., Dunkel M., & Preissner R. (2014). SuperPred: Update on drug classification and target prediction. Nucleic Acids Research, 42(Web Server issue), W26\u201331. 10.1093/nar/gku477", "ArticleIdList": ["10.1093/nar/gku477", "PMC4086135", "24878925"]}, {"Citation": "O'Boyle N. M., Banck M., James C. A., Morley C., Vandermeersch T., & Hutchison G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33.10.1186/1758-2946-3-33", "ArticleIdList": ["10.1186/1758-2946-3-33", "PMC3198950", "21982300"]}, {"Citation": "Osafo N., Mensah K. B., & Yeboah O. K. (2017). Phytochemical and pharmacological review of Cryptolepis sanguinolenta (Lindl.) schlechter. Adv Pharmacol Sci, 2017, 3026370.10.1155/2017/3026370", "ArticleIdList": ["10.1155/2017/3026370", "PMC5661077", "29750083"]}, {"Citation": "Pant S., Singh M., Ravichandiran V., Murty U., & Srivastava H. K. (2020). Peptide-like and small-molecule inhibitors against Covid-19. Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201315.", "ArticleIdList": ["PMC7212534", "32306822"]}, {"Citation": "Pelz N. F., Bian Z., Zhao B., Shaw S., Tarr J. C., Belmar J., Gregg C., Camper D. V., Goodwin C. M., Arnold A. L., Sensintaffar J. L., Friberg A., Rossanese O. W., Lee T., Olejniczak E. T., & Fesik S. W. (2016). Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods . J. Med. Chem, 59(5), 2054\u20132066. 10.1021/acs.jmedchem.5b01660", "ArticleIdList": ["10.1021/acs.jmedchem.5b01660", "PMC5565212", "26878343"]}, {"Citation": "Pillaiyar T., Manickam M., Namasivayam V., Hayashi Y., & Jung S. H. (2016). An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. Journal of Medicinal Chemistry, 59(14), 6595\u20136628. 10.1021/acs.jmedchem.5b01461", "ArticleIdList": ["10.1021/acs.jmedchem.5b01461", "PMC7075650", "26878082"]}, {"Citation": "Sanchez-Linares I., Perez-Sanchez H., Cecilia J. M., & Garcia J. M. (2012). High-Throughput parallel blind Virtual Screening using BINDSURF. BMC Bioinformatics, 13(Suppl 14), S13 10.1186/1471-2105-13-s14-s13", "ArticleIdList": ["10.1186/1471-2105-13-s14-s13", "PMC3504923", "23095663"]}, {"Citation": "Sang P.,\nTian S.,\nMeng Z.,\nYang L. (2020). Insight\nderived from molecular docking and molecular dynamics simulations into the binding\ninteractions between HIV-1 protease inhibitor s and SARS-CoV-2 3CLpro.\nPreprint.\nhttps://chemrxiv.org/articles/Insight_Derived_from_Molecular_Docking_and_Molecular_Dynamics_Simulations_into_the_Binding_Interactions_Between_HIV-1_Protease_Inhibitors_and_SARS-CoV-2_3CLpro/11932995/1."}, {"Citation": "Sarma P., Sekhar N., Prajapat M., Avti P., Kaur H., Kumar S., & Dhibar D. P. (2020). In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). Journal of Biomolecular Structure and Dynamics, (just-accepted), 1\u201311.", "ArticleIdList": ["PMC7256351", "32266867"]}, {"Citation": "Setzer W. N., Holland M. T., Bozeman C. A., Rozmus G. F., Setzer M. C., Moriarity D. M., Reeb S., Vogler B., Bates R. B., & Haber W. A. (2001). Isolation and frontier molecular orbital investigation of bioactive quinone-methide triterpenoids from the bark of Salacia petenensis. Planta Medica, 67(1), 65\u201369. 10.1055/s-2001-10879", "ArticleIdList": ["10.1055/s-2001-10879", "11270725"]}, {"Citation": "Souers A. J., Leverson J. D., Boghaert E. R., Ackler S. L., Catron N. D., Chen J., Dayton B. D., Ding H., Enschede S. H., Fairbrother W. J., Huang D. C. S., Hymowitz S. G., Jin S., Khaw S. L., Kovar P. J., Lam L. T., Lee J., Maecker H. L., Marsh K. C., \u2026 Elmore S. W. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202\u2013208. 10.1038/nm.3048", "ArticleIdList": ["10.1038/nm.3048", "23291630"]}, {"Citation": "Trott O., & Olson A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455\u2013461. 10.1002/jcc.21334", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Ul Qamar M. T., Alqahtani S. M., Alamri M. A., & Chen L.-L. (2020). Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Journal of Pharmaceutical Analysis. 10.1016/j.jpha.2020.03.009", "ArticleIdList": ["10.1016/j.jpha.2020.03.009", "PMC7156227", "32296570"]}, {"Citation": "Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., & Xiao G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269\u2013271. 10.1038/s41422-020-0282-0", "ArticleIdList": ["10.1038/s41422-020-0282-0", "PMC7054408", "32020029"]}, {"Citation": "Who W.-C J. (2020). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva 2020."}, {"Citation": "Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., Zheng M., Chen L., & Li H. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 10.1016/j.apsb.2020.02.008", "ArticleIdList": ["10.1016/j.apsb.2020.02.008", "PMC7102550", "32292689"]}, {"Citation": "Xu Z., Peng C., Shi Y., Zhu Z., Mu K., Wang X., & Zhu W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. BioRxiv, 1, 0\u20132."}, {"Citation": "Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., Sun L., Mo L., Ye S., Pang H., Gao G. F., Anand K., Bartlam M., Hilgenfeld R., & Rao Z. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13190\u201313195. 10.1073/pnas.1835675100", "ArticleIdList": ["10.1073/pnas.1835675100", "PMC263746", "14585926"]}, {"Citation": "Zhao Q., Li S., Xue F., Zou Y., Chen C., Bartlam M., & Rao Z. (2008). Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. Journal of Virology, 82(17), 8647\u20138655. 10.1128/jvi.00298-08", "ArticleIdList": ["10.1128/jvi.00298-08", "PMC2519634", "18562531"]}, {"Citation": "Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Chen H.-D., Chen J., Luo Y., Guo H., Jiang R.-D., Liu M.-Q., Chen Y., Shen X.-R., Wang X., \u2026 Shi Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270\u2013273. 10.1038/s41586-020-2012-7", "ArticleIdList": ["10.1038/s41586-020-2012-7", "PMC7095418", "32015507"]}, {"Citation": "Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G. F., & Tan W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine, 382(8), 727\u2013733. 10.1056/NEJMoa2001017", "ArticleIdList": ["10.1056/NEJMoa2001017", "PMC7092803", "31978945"]}, {"Citation": "Zumla A., Chan J. F., Azhar E. I., Hui D. S., & Yuen K. Y. (2016). Coronaviruses - drug discovery and therapeutic options. Nature Reviews. Drug Discovery, 15(5), 327\u2013347. 10.1038/nrd.2015.37", "ArticleIdList": ["10.1038/nrd.2015.37", "PMC7097181", "26868298"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "5", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "5", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "5", "Day": "29"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32367767", "PMC7256353", "10.1080/07391102.2020.1764868"]}}], "PubmedBookArticle": []}